Predicting Dropout and Outcome From Neuropsychological Functions in SUD Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03220373|
Recruitment Status : Recruiting
First Posted : July 18, 2017
Last Update Posted : August 1, 2017
|Condition or disease|
|Substance Use Disorder (SUD)|
This project collects the neuropsychological profile of residential SUD patients, in addition to treatment length, exit reason, hospital journal data and post-treatment clinical outcome data. The project aims to identify clinically relevant neurocognitive domains that predict treatment dropout and post-treatment clinical outcome. This will make it possible for future clinicians to focus their effort on neurocognitive functions most relevant for this particular patient group.
- What neurocognitive domain (and sub-domain) are the strongest predictor of treatment drop-out and retention?
- What neurocognitive domain (and sub-domain) are the strongest predictor of post-treatment clinical outcome variables such as drug use, health and social integration.
- Will data on treatment length, age, gender, substance abuse history or psychiatric co-morbidity predict outcome independently, or in interaction with, the neuropsychological profile?
This longitudinal prospective cohort study aims for a continuous collection of neuropsychological data baseline and post-treatment follow-up data until 2030.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Predicting Early Treatment Termination (Dropout) and Post-treatment Clinical Outcome From Neuropsychological Functions in Abstinent Substance Use Dependent (SUD) Patients|
|Actual Study Start Date :||March 7, 2017|
|Estimated Primary Completion Date :||December 31, 2029|
|Estimated Study Completion Date :||December 31, 2029|
- Exit reason [ Time Frame: On average 3 months ]Reason for terminating residential SUD treatment (Treatment completed or Drop-out)
- Treatment retention [ Time Frame: On average 3 months ]Number of days in treatment
- Substance use [ Time Frame: 1 year after neuropsychological assessment ]DUDIT (Drug Use Disorders Identification Test)
- Psychological distress [ Time Frame: 1 year after neuropsychological assessment ]SCL-10 (Symptom Checklist)
- Quality of Life [ Time Frame: 1 year after neuropsychological assessment ]QoL-5 (Quality of Life)
- ADHD symptoms [ Time Frame: 1 year after neuropsychological assessment ]ASRS (ADHD Self-Report Scale)
- Income [ Time Frame: 1 year after neuropsychological assessment ]Nature of income
- Housing [ Time Frame: 1 year after neuropsychological assessment ]Nature of present accommodation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03220373
|Contact: Espen Walderhaug, PhD||+47 email@example.com|
|Contact: Arne Holen, PsyD||+47 firstname.lastname@example.org|
|Oslo University Hospital||Recruiting|
|Oslo, Norway, 0320|
|Principal Investigator:||Espen Walderhaug, PhD||Oslo University Hospital|